Prevalence of use and acute toxicity associated with the use of NBOMe drugs. - Wikidata - awgldk - TriplyDB

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

http://www.wikidata.org/entity/Q38346439

about

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants NPS: Medical Consequences Associated with Their Intake Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System.New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics.Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs.Recommendations for specimen collection for NBOMe analysis in clinical toxicology.Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases.Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.

P2860

Q26752739-1E2271FB-6253-4ED5-A577-2C000C514F01 Q28276182-9E9F030B-3B58-4B61-8769-616FDACC7598 Q30251771-DBCBEF1D-44B2-4AB7-8B29-D48032F19937 Q30969880-811AEB03-886C-4EBF-9C6F-042A2F92129F Q38963846-841CEA60-4B93-494A-A5B9-CC8AF41B8A03 Q39093171-BB29D7C0-456D-423F-B472-7380D1E29524 Q41759552-2D4F3EEA-4A1F-497C-A98B-BA647DA29951 Q42379355-6D82B9F4-00A8-4A00-AE8E-60A549F22583 Q48069477-356A6248-D41B-4264-B677-47E73C7A5A5B Q50627353-05B7F73F-0F5C-4C1B-B0A2-2A30E21C7EB6 Q51482161-031A35DD-78E2-48EE-9CC2-B1CAE2A1248A Q53063534-3EEDA4E1-EFE5-4594-B3F9-F28AD3F60847

P2860

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

http://www.wikidata.org/entity/Q38346439

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

@en

type

label

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

@en

prefLabel

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

@en

P1433

Q38346439-389B6E57-4B74-49D7-AC13-22AE20FB759F

P1476

Q38346439-58FD43CC-165E-4640-B1E7-4411AA538692

P2093

Q38346439-45E18128-6975-4358-A318-ECF948734DAB

Q38346439-5EB570DE-745D-4B2B-A550-DD9FFCCC2900

Q38346439-C7E46FA6-F88F-405D-BBAA-F111F4D616CD

Q38346439-E1796312-4A69-40A6-B013-F4CF7CCE12CE

P2860

Q38346439-04E8C606-591A-4925-B965-D1275853AAF6

Q38346439-36761BC5-8375-4A9B-8E64-58CE04CEBAD4

Q38346439-46D8F8AC-55D4-4C33-8D19-C0C70D33D4D2

Q38346439-4B301666-144F-4D8A-9444-3E0F4D443E1F

Q38346439-586A4997-1651-470D-BF37-B544600C25F9

Q38346439-7713C582-44D3-420A-8C2A-D22B8265B9F4

Q38346439-8E38BF8E-D177-41FD-A5F5-03BD244154C5

Q38346439-94BF4B48-5100-4002-84A3-2985452D6B9B

Q38346439-98F447B2-BDE5-4CC4-ADC0-DC4B9CC559CD

Q38346439-9EFB7A5A-4053-4642-9E02-83F19A91AF10

P304

Q38346439-A8F8B295-43C2-4865-AAC1-431DC21661A7

P31

Q38346439-9B3D63DE-A10B-4949-83C0-30BECDE97BEF

P356

Q38346439-0F5D088A-591B-4C56-96A8-01F6785E4BB2

P407

Q38346439-290C3A6D-7301-4EB9-BDB8-74C4C6C23878

P433

Q38346439-A4ECC014-3CB5-4B20-985C-F8838D401838

P478

Q38346439-E4584F81-6DBD-4912-984C-906CC385C29A

P577

Q38346439-F23372D2-BC73-428A-BAD9-FC2918794CE5

P5875

Q38346439-64D3BDE5-2CD7-473C-9E0D-B42CAAADDBBD

P698

Q38346439-B9B564B4-F638-429B-B252-06BA72677026

P356

15563650.2015.1004179

P1433

Clinical Toxicology

P1476

Prevalence of use and acute toxicity associated with the use of NBOMe drugs.

@en

P2093

Andrew Cunningham

http://www.w3.org/2001/XMLSchema#string

David M Wood

http://www.w3.org/2001/XMLSchema#string

Paul I Dargan

http://www.w3.org/2001/XMLSchema#string

Roumen Sedefov

http://www.w3.org/2001/XMLSchema#string

P2860

2013 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)

2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)

High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum.

A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug.

Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series.

The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.

[Near fatal intoxication with the novel psychoactive substance 25C-NBOMe].

Limited use of novel psychoactive substances in South London nightclubs.

2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.

Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.

P304

85-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/15563650.2015.1004179

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272077222

http://www.w3.org/2001/XMLSchema#string

P698

25658166

http://www.w3.org/2001/XMLSchema#string